EXCEDRIN (MIGRAINE RELIEF)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EXCEDRIN (MIGRAINE RELIEF) (EXCEDRIN (MIGRAINE RELIEF)).
Acetaminophen: inhibits COX enzymes centrally, reducing prostaglandin synthesis; Aspirin: irreversibly acetylates COX-1 and COX-2, inhibiting prostaglandin synthesis and platelet aggregation; Caffeine: adenosine receptor antagonist, enhances analgesic effect by vasoconstriction and increased drug absorption.
| Metabolism | Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4 (minor), conjugation; Aspirin: hepatic hydrolysis to salicylate, then conjugation; Caffeine: hepatic via CYP1A2. |
| Excretion | Renal excretion: acetaminophen ~3% unchanged, metabolites (glucuronide, sulfate, cysteine, mercapturate) ~85%; aspirin as salicylic acid ~10% unchanged, metabolites (salicyluric acid, glucuronides) ~75% renal; caffeine ~1-5% unchanged, metabolites (paraxanthine, theobromine, theophylline) ~70% renal. Biliary/fecal <5%. |
| Half-life | Acetaminophen: 2-3 hours (terminal); aspirin: 15-20 minutes (parent), salicylic acid: 2-3 hours (low dose), 15-30 hours (high dose); caffeine: 3-7 hours (adults). Clinical context: Half-lives prolonged in hepatic impairment, overdose, or renal failure. |
| Protein binding | Acetaminophen: 10-25% (albumin); aspirin: 80-90% (salicylic acid, albumin); caffeine: 25-36% (albumin). |
| Volume of Distribution | Acetaminophen: 0.9-1.0 L/kg (distributes uniformly); aspirin: 0.15-0.2 L/kg (low dose, predominantly plasma); caffeine: 0.6-0.8 L/kg (distributes into total body water). Clinical meaning: Vd indicates tissue penetration and loading dose requirements. |
| Bioavailability | Acetaminophen: oral 85-98%; aspirin: oral 50-70% (due to first-pass hydrolysis); caffeine: oral 99% (almost complete absorption). |
| Onset of Action | Oral: acetaminophen: 30-60 minutes; aspirin: 30-60 minutes; caffeine: 30-60 minutes. All via oral route. |
| Duration of Action | Acetaminophen: 4-6 hours; aspirin: 4-6 hours (low dose), 6-8 hours (high dose); caffeine: 4-6 hours. Clinical notes: Duration may be extended with sustained-release or hepatic impairment. |
2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine) orally every 6 hours as needed, not to exceed 6 tablets in 24 hours.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-60 mL/min: Reduce dose by 50% and monitor renal function. eGFR <30 mL/min: Avoid use due to aspirin and acetaminophen accumulation. |
| Liver impairment | Child-Pugh class A: No adjustment. Child-Pugh class B: Reduce dose by 50% and monitor hepatic function. Child-Pugh class C: Contraindicated. |
| Pediatric use | Not recommended for children under 18 years due to risk of Reye's syndrome (aspirin component). |
| Geriatric use | Use lowest effective dose; monitor for gastrointestinal bleeding, renal impairment, and caffeine-related side effects. Consider alternative agents due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EXCEDRIN (MIGRAINE RELIEF) (EXCEDRIN (MIGRAINE RELIEF)).
| Breastfeeding | Acetaminophen and caffeine are excreted into breast milk in small amounts; aspirin is excreted and may pose risk of Reye syndrome in infants. M/P ratio: acetaminophen ~1.0, aspirin ~0.6, caffeine ~0.6. Use with caution, preferably avoid due to aspirin. |
| Teratogenic Risk | Acetaminophen is considered low risk; aspirin is associated with increased risk of fetal hemorrhage and premature closure of ductus arteriosus, especially in third trimester; caffeine is not associated with major malformations at typical doses. Overall, Excedrin Migraine is contraindicated in third trimester due to aspirin component. |
■ FDA Black Box Warning
Reye's syndrome risk in children/adolescents with viral illness (due to aspirin).
| Serious Effects |
Hypersensitivity to any component, active peptic ulcer disease, hemophilia, severe hepatic impairment, children/adolescents with viral illness (Reye's syndrome), third trimester of pregnancy (aspirin).
| Precautions | Hepatotoxicity (acetaminophen overdose), bleeding risk (aspirin), gastritis/GI ulceration, renal impairment, hypersensitivity reactions (including asthma with aspirin). |
Loading safety data…
| Fetal Monitoring | Monitor for maternal bleeding, fetal ultrasound for ductus arteriosus patency in third trimester, and neonatal bleeding if used near term. |
| Fertility Effects | No significant effects on fertility reported for acetaminophen or caffeine; aspirin may inhibit ovulation at high doses, but clinical significance is unclear. |